245 related articles for article (PubMed ID: 30465867)
1. Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis.
Yamada T; Kashiwagi Y; Rokugawa T; Kato H; Konishi H; Hamada T; Nagai R; Masago Y; Itoh M; Suganami T; Ogawa Y; Abe K
Magn Reson Imaging; 2019 Apr; 57():210-217. PubMed ID: 30465867
[TBL] [Abstract][Full Text] [Related]
2. Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice.
Yamada T; Obata A; Kashiwagi Y; Rokugawa T; Matsushima S; Hamada T; Watabe H; Abe K
Magn Reson Imaging; 2016 Jul; 34(6):724-729. PubMed ID: 26979540
[TBL] [Abstract][Full Text] [Related]
3. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging.
Tsuda N; Okada M; Murakami T
Invest Radiol; 2007 Apr; 42(4):242-7. PubMed ID: 17351431
[TBL] [Abstract][Full Text] [Related]
4. Correlation of histologic, imaging, and artificial intelligence features in NAFLD patients, derived from Gd-EOB-DTPA-enhanced MRI: a proof-of-concept study.
Bastati N; Perkonigg M; Sobotka D; Poetter-Lang S; Fragner R; Beer A; Messner A; Watzenboeck M; Pochepnia S; Kittinger J; Herold A; Kristic A; Hodge JC; Traussnig S; Trauner M; Ba-Ssalamah A; Langs G
Eur Radiol; 2023 Nov; 33(11):7729-7743. PubMed ID: 37358613
[TBL] [Abstract][Full Text] [Related]
5. The natural history of streptozotocin-stimulated non-alcoholic steatohepatitis mice followed by Gd-EOB-DTPA-enhanced MRI: Comparison with simple steatosis mice.
Akai H; Kiryu S; Ohta Y; Yasaka K; Nakano Y; Inoue Y; Ohtomo K
Magn Reson Imaging; 2017 May; 38():123-128. PubMed ID: 28062263
[TBL] [Abstract][Full Text] [Related]
6. New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI.
Tsuda N; Okada M; Murakami T
Eur J Radiol; 2010 Jan; 73(1):137-42. PubMed ID: 19026502
[TBL] [Abstract][Full Text] [Related]
7. Gd-EOB-DTPA-enhanced T1ρ imaging vs diffusion metrics for assessment liver inflammation and early stage fibrosis of nonalcoholic steatohepatitis in rabbits.
Xie Y; Zhang H; Jin C; Wang X; Wang X; Chen J; Xu Y
Magn Reson Imaging; 2018 May; 48():34-41. PubMed ID: 29278765
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of Gd-EOB-DTPA-enhanced MR imaging in the evaluation of simple steatosis and nonalcoholic steatohepatitis.
Wu Z; Matsui O; Kitao A; Kozaka K; Koda W; Kobayashi S; Ryu Y; Minami T; Sanada J; Gabata T
J Magn Reson Imaging; 2013 May; 37(5):1137-43. PubMed ID: 23172731
[TBL] [Abstract][Full Text] [Related]
9. Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice.
Konuma K; Itoh M; Suganami T; Kanai S; Nakagawa N; Sakai T; Kawano H; Hara M; Kojima S; Izumi Y; Ogawa Y
PLoS One; 2015; 10(3):e0121528. PubMed ID: 25816330
[TBL] [Abstract][Full Text] [Related]
10. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis.
Itoh M; Suganami T; Nakagawa N; Tanaka M; Yamamoto Y; Kamei Y; Terai S; Sakaida I; Ogawa Y
Am J Pathol; 2011 Nov; 179(5):2454-63. PubMed ID: 21906580
[TBL] [Abstract][Full Text] [Related]
11. A simple and inexpensive system for controlling body temperature in small animal experiments using MRI and the effect of body temperature on the hepatic kinetics of Gd-EOB-DTPA.
Murase K; Assanai P; Takata H; Saito S; Nishiura M
Magn Reson Imaging; 2013 Dec; 31(10):1744-51. PubMed ID: 24094686
[TBL] [Abstract][Full Text] [Related]
12. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis.
Waghorn PA; Ferreira DS; Erstad DJ; Rotile NJ; Masia R; Jones CM; Tu C; Sojoodi M; Chen YI; Schlerman F; Wellen J; Martinez RVP; Tanabe KK; Fuchs BC; Caravan P
Sci Rep; 2021 Mar; 11(1):6105. PubMed ID: 33731798
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast-enhanced MRI of the liver in Mrp2-deficient rats using the hepatobiliary contrast agent Gd-EOB-DTPA.
Saito S; Obata A; Kashiwagi Y; Abe K; Murase K
Invest Radiol; 2013 Jul; 48(7):548-53. PubMed ID: 23442774
[TBL] [Abstract][Full Text] [Related]
14. Molecular MR Imaging of Myeloperoxidase Distinguishes Steatosis from Steatohepatitis in Nonalcoholic Fatty Liver Disease.
Pulli B; Wojtkiewicz G; Iwamoto Y; Ali M; Zeller MW; Bure L; Wang C; Choi Y; Masia R; Guimaraes AR; Corey KE; Chen JW
Radiology; 2017 Aug; 284(2):390-400. PubMed ID: 28358240
[TBL] [Abstract][Full Text] [Related]
15. Unenhanced fat fraction ratios obtained by MR and enhanced T2* values with liver-specific MR contrast agents for diagnosis of non-alcoholic steatohepatitis in rats.
Okada M; Katsube T; Kumano S; Kagawa Y; Araki T; Tsuda N; Okuaki T; Imaoka I; Tanigawa N; Ishii K; Murakami T
Acta Radiol; 2011 Jul; 52(6):658-64. PubMed ID: 21498305
[TBL] [Abstract][Full Text] [Related]
16. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
[TBL] [Abstract][Full Text] [Related]
17. C-type natriuretic peptide (CNP) in endothelial cells attenuates hepatic fibrosis and inflammation in non-alcoholic steatohepatitis.
Bae CR; Hino J; Hosoda H; Miyazato M; Kangawa K
Life Sci; 2018 Sep; 209():349-356. PubMed ID: 30114411
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease.
Ding Y; Rao SX; Meng T; Chen C; Li R; Zeng MS
Eur Radiol; 2014 Apr; 24(4):959-66. PubMed ID: 24463697
[TBL] [Abstract][Full Text] [Related]
19. Non-contrast T1ρ dispersion versus Gd-EOB-DTPA-enhanced T1mapping for the risk stratification of non-alcoholic fatty liver disease in rabbit models.
Yang R; Chen Z; Pan J; Yang S; Hu F
Magn Reson Imaging; 2024 Apr; 107():130-137. PubMed ID: 38278311
[TBL] [Abstract][Full Text] [Related]
20. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
Shiba K; Tsuchiya K; Komiya C; Miyachi Y; Mori K; Shimazu N; Yamaguchi S; Ogasawara N; Katoh M; Itoh M; Suganami T; Ogawa Y
Sci Rep; 2018 Feb; 8(1):2362. PubMed ID: 29402900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
